Journal
NEPHRON CLINICAL PRACTICE
Volume 112, Issue 4, Pages C230-C240Publisher
KARGER
DOI: 10.1159/000224789
Keywords
PPAR-gamma agonists; Thiazolidinediones; Kidney disease; Diabetes mellitus
Categories
Funding
- International Society of Nephrology (ISN)
- Changzheng Hospital
Ask authors/readers for more resources
The peroxisome proliferator-activated receptor superfamily (PPARs) comprises a class of nuclear receptors with significant effects in regulating multiple cellular pathways. Much research and clinical interest has surrounded the PPAR-gamma isoform because of its key role in the transcriptional regulation of metabolic pathways and the efficacy of thiazolidinediones, the most clinically used PPAR-gamma agonist, in the management of type 2 diabetes mellitus. In this review, we discuss the pathogenic role of PPAR-gamma in experimental models of kidney disease, clinical trials of thiazolidinediones in diabetic and non-diabetic kidney disease, recent safety concerns surrounding PPAR-gamma agonists and reflect on their potential use in 'orphan' kidney diseases. Copyright (C) 2009 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available